Skip to content

Study · Non-randomized trial · 1992

20 results

Octreotide treatment of acromegaly. A randomized, multicenter study.

Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM

Annals of internal medicine1 Nov 1992Cited by 150 (Europe PMC)

PMID1416572 (opens in a new tab)DOI10.7326/0003-4819-117-9-711 (opens in a new tab)PepBankPUB-01416572
Publisher pagePubMedAsk about this study
Jump to 20 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study20

20 results from studies that gave the peptide. 20 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In acromegaly patients after 2 weeks of treatment, one octreotide injection reduced GH to 30% of pretreatment within 2 hours.

    In plain wordsIn acromegaly patients, one octreotide injection reduced GH to 30% of its pretreatment concentration within 2 hours.

    Peptide
    Octreotide
    Outcome
    DecreaseAcute GH concentration
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 micrograms · subcutaneousAs given in this study (human).

    Measurements

    Mean serum GH as percent of pretreatment concentration
    30%
    within 2 hours of a single 100-microgram injection, after 2 weeks of treatment

    Source sentences

    Summary
    After 2 weeks of treatment, a single 100-micrograms injection reduced mean serum growth hormone (GH) to 30% of the pretreatment concentration within 2 hours.
    3 context sentences
    Summary · context
    One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.
    Summary · context
    Subcutaneous octreotide, 100 micrograms, or placebo every 8 hours for 4 weeks.
    Summary · context
    Four weeks after the end of treatment, patients were randomized to receive 100 or 250 micrograms octreotide subcutaneously every 8 hours for 6 months.
  2. 02HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, octreotide reduced integrated GH from 39 +/- 11 to 9 +/- 2 micrograms/L over 8 hours (P less than 0.001).

    In plain wordsIn acromegaly patients, octreotide reduced integrated GH compared with pretreatment.

    Peptide
    Octreotide
    Outcome
    DecreaseIntegrated GH over 8 hours
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Integrated mean GH over 8 hours
    39 micrograms/L
    before treatment (+/- 11)
    Integrated mean GH over 8 hours
    9 micrograms/L
    after treatment (+/- 2)

    Source sentences

    Summary
    The integrated mean GH level was reduced over 8 hours from 39 +/- 11 micrograms/L to 9 +/- 2 micrograms/L (P less than 0.001).
    3 context sentences
    Summary · context
    One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.
    Summary · context
    Subcutaneous octreotide, 100 micrograms, or placebo every 8 hours for 4 weeks.
    Summary · context
    Four weeks after the end of treatment, patients were randomized to receive 100 or 250 micrograms octreotide subcutaneously every 8 hours for 6 months.
  3. 03HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, octreotide reduced IGF-1 from 5100 +/- 400 to 2400 +/- 400 U/L (P less than 0.001).

    In plain wordsIn acromegaly patients, octreotide reduced IGF-1 compared with pretreatment.

    Peptide
    Octreotide
    Outcome
    DecreasePlasma IGF-1
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Mean plasma IGF-1
    5100 U/L
    before treatment (+/- 400)
    Mean plasma IGF-1
    2400 U/L
    after treatment (+/- 400)

    Source sentences

    Summary
    Mean plasma insulin-like growth factor-1 (IGF-1) was reduced from 5100 +/- 400 U/L to 2400 +/- 400 U/L (P less than 0.001).
    3 context sentences
    Summary · context
    One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.
    Summary · context
    Subcutaneous octreotide, 100 micrograms, or placebo every 8 hours for 4 weeks.
    Summary · context
    Four weeks after the end of treatment, patients were randomized to receive 100 or 250 micrograms octreotide subcutaneously every 8 hours for 6 months.
  4. 04HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, low-dose octreotide reduced GH from 39 +/- 13 to 15 +/- 4 micrograms/L after 6 months.

    In plain wordsIn acromegaly patients, low-dose octreotide reduced GH from pretreatment after 6 months.

    Peptide
    Octreotide
    Outcome
    DecreaseGH at 6 months, low dose
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    300 micrograms daily · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Mean GH
    39 micrograms/L
    before treatment, 300 micrograms octreotide group (+/- 13)
    Mean GH
    15 micrograms/L
    after 6 months, 300 micrograms octreotide (+/- 4)

    Source sentences

    Summary
    After 6 months, the mean GH was reduced from 39 +/- 13 to 15 +/- 4 micrograms/L by 300 micrograms of octreotide and from 29 +/- 5 micrograms/L to 9 +/- 2 micrograms/L by 750 micrograms of octreotide daily.
    3 context sentences
    Summary · context
    One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.
    Summary · context
    Subcutaneous octreotide, 100 micrograms, or placebo every 8 hours for 4 weeks.
    Summary · context
    Four weeks after the end of treatment, patients were randomized to receive 100 or 250 micrograms octreotide subcutaneously every 8 hours for 6 months.
  5. 05HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, high-dose octreotide reduced GH from 29 +/- 5 to 9 +/- 2 micrograms/L after 6 months.

    In plain wordsIn acromegaly patients, high-dose octreotide reduced GH from pretreatment after 6 months.

    Peptide
    Octreotide
    Outcome
    DecreaseGH at 6 months, high dose
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    750 micrograms daily · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Mean GH
    29 micrograms/L
    before treatment, 750 micrograms octreotide group (+/- 5)
    Mean GH
    9 micrograms/L
    after 6 months, 750 micrograms daily octreotide (+/- 2)

    Source sentences

    Summary
    After 6 months, the mean GH was reduced from 39 +/- 13 to 15 +/- 4 micrograms/L by 300 micrograms of octreotide and from 29 +/- 5 micrograms/L to 9 +/- 2 micrograms/L by 750 micrograms of octreotide daily.
    3 context sentences
    Summary · context
    One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.
    Summary · context
    Subcutaneous octreotide, 100 micrograms, or placebo every 8 hours for 4 weeks.
    Summary · context
    Four weeks after the end of treatment, patients were randomized to receive 100 or 250 micrograms octreotide subcutaneously every 8 hours for 6 months.
  6. 06HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, low-dose octreotide suppressed IGF-1 to 2100 +/- 300 U/L.

    In plain wordsIn acromegaly patients, low-dose octreotide reduced IGF-1 compared with pretreatment.

    Peptide
    Octreotide
    Outcome
    DecreaseIGF-1 at low dose
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    300 micrograms daily · subcutaneousAs given in this study (human).

    Measurements

    Mean IGF-1 concentration
    2100 U/L
    after 300 micrograms octreotide (+/- 300)

    Source sentences

    Summary
    The mean IGF-1 concentration was suppressed to 2100 +/- 300 and 2500 +/- 400 U/L after 300 and 750 micrograms octreotide, respectively.
    3 context sentences
    Summary · context
    One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.
    Summary · context
    Subcutaneous octreotide, 100 micrograms, or placebo every 8 hours for 4 weeks.
    Summary · context
    Four weeks after the end of treatment, patients were randomized to receive 100 or 250 micrograms octreotide subcutaneously every 8 hours for 6 months.
  7. 07HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, high-dose octreotide suppressed IGF-1 to 2500 +/- 400 U/L.

    In plain wordsIn acromegaly patients, high-dose octreotide reduced IGF-1 compared with pretreatment.

    Peptide
    Octreotide
    Outcome
    DecreaseIGF-1 at high dose
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    750 micrograms daily · subcutaneousAs given in this study (human).

    Measurements

    Mean IGF-1 concentration
    2500 U/L
    after 750 micrograms octreotide (+/- 400)

    Source sentences

    Summary
    The mean IGF-1 concentration was suppressed to 2100 +/- 300 and 2500 +/- 400 U/L after 300 and 750 micrograms octreotide, respectively.
    3 context sentences
    Summary · context
    One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.
    Summary · context
    Subcutaneous octreotide, 100 micrograms, or placebo every 8 hours for 4 weeks.
    Summary · context
    Four weeks after the end of treatment, patients were randomized to receive 100 or 250 micrograms octreotide subcutaneously every 8 hours for 6 months.
  8. 08HumanNon-randomized trialEfficacy outcome

    In acromegaly patients receiving low-dose octreotide, 53% had integrated GH below 5 micrograms/L (95% CI, 39% to 67%).

    In plain wordsIn acromegaly patients receiving low-dose octreotide, 53% reached GH below 5 micrograms/L.

    Peptide
    Octreotide
    Outcome
    Not applicableGH responder proportion, low dose
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    300 micrograms daily · subcutaneousAs given in this study (human).

    Measurements

    Patients with integrated mean GH below 5 micrograms/L
    53%
    low-dose octreotide
    95% CI for proportion
    39 to 67%
    low-dose octreotide

    Source sentences

    Summary
    Integrated mean GH levels were reduced to < 5 micrograms/L in 53% (95% CI, 39% to 67%) and 49% (CI, 35% to 63%), and IGF-1 levels were normal in 68% (CI, 54% to 82%) and 55% (CI, 40% to 70%) of patients receiving low- and high-dose octreotide, respectively.
    3 context sentences
    Summary · context
    One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.
    Summary · context
    Subcutaneous octreotide, 100 micrograms, or placebo every 8 hours for 4 weeks.
    Summary · context
    Four weeks after the end of treatment, patients were randomized to receive 100 or 250 micrograms octreotide subcutaneously every 8 hours for 6 months.
  9. 09HumanNon-randomized trialEfficacy outcome

    In acromegaly patients receiving high-dose octreotide, 49% had integrated GH below 5 micrograms/L (CI, 35% to 63%).

    In plain wordsIn acromegaly patients receiving high-dose octreotide, 49% reached GH below 5 micrograms/L.

    Peptide
    Octreotide
    Outcome
    Not applicableGH responder proportion, high dose
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    750 micrograms daily · subcutaneousAs given in this study (human).

    Measurements

    Patients with integrated mean GH below 5 micrograms/L
    49%
    high-dose octreotide
    CI for proportion
    35 to 63%
    high-dose octreotide

    Source sentences

    Summary
    Integrated mean GH levels were reduced to < 5 micrograms/L in 53% (95% CI, 39% to 67%) and 49% (CI, 35% to 63%), and IGF-1 levels were normal in 68% (CI, 54% to 82%) and 55% (CI, 40% to 70%) of patients receiving low- and high-dose octreotide, respectively.
    3 context sentences
    Summary · context
    One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.
    Summary · context
    Subcutaneous octreotide, 100 micrograms, or placebo every 8 hours for 4 weeks.
    Summary · context
    Four weeks after the end of treatment, patients were randomized to receive 100 or 250 micrograms octreotide subcutaneously every 8 hours for 6 months.
  10. 10HumanNon-randomized trialEfficacy outcome

    In acromegaly patients receiving low-dose octreotide, 68% had normal IGF-1 (CI, 54% to 82%).

    In plain wordsIn acromegaly patients receiving low-dose octreotide, 68% had normal IGF-1.

    Peptide
    Octreotide
    Outcome
    Not applicableNormal IGF-1, low dose
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    300 micrograms daily · subcutaneousAs given in this study (human).

    Measurements

    Patients with normal IGF-1
    68%
    low-dose octreotide
    CI for proportion
    54 to 82%
    low-dose octreotide

    Source sentences

    Summary
    Integrated mean GH levels were reduced to < 5 micrograms/L in 53% (95% CI, 39% to 67%) and 49% (CI, 35% to 63%), and IGF-1 levels were normal in 68% (CI, 54% to 82%) and 55% (CI, 40% to 70%) of patients receiving low- and high-dose octreotide, respectively.
    3 context sentences
    Summary · context
    One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.
    Summary · context
    Subcutaneous octreotide, 100 micrograms, or placebo every 8 hours for 4 weeks.
    Summary · context
    Four weeks after the end of treatment, patients were randomized to receive 100 or 250 micrograms octreotide subcutaneously every 8 hours for 6 months.
  11. 11HumanNon-randomized trialEfficacy outcome

    In acromegaly patients receiving high-dose octreotide, 55% had normal IGF-1 (CI, 40% to 70%).

    In plain wordsIn acromegaly patients receiving high-dose octreotide, 55% had normal IGF-1.

    Peptide
    Octreotide
    Outcome
    Not applicableNormal IGF-1, high dose
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    750 micrograms daily · subcutaneousAs given in this study (human).

    Measurements

    Patients with normal IGF-1
    55%
    high-dose octreotide
    CI for proportion
    40 to 70%
    high-dose octreotide

    Source sentences

    Summary
    Integrated mean GH levels were reduced to < 5 micrograms/L in 53% (95% CI, 39% to 67%) and 49% (CI, 35% to 63%), and IGF-1 levels were normal in 68% (CI, 54% to 82%) and 55% (CI, 40% to 70%) of patients receiving low- and high-dose octreotide, respectively.
    3 context sentences
    Summary · context
    One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.
    Summary · context
    Subcutaneous octreotide, 100 micrograms, or placebo every 8 hours for 4 weeks.
    Summary · context
    Four weeks after the end of treatment, patients were randomized to receive 100 or 250 micrograms octreotide subcutaneously every 8 hours for 6 months.
  12. 12HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, octreotide substantially decreased headache, perspiration, joint pain, and finger circumference in two thirds of patients.

    In plain wordsIn acromegaly patients, octreotide decreased the reported symptoms and finger circumference in two thirds of patients.

    Peptide
    Octreotide
    Outcome
    DecreaseSymptoms and finger circumference
    Study

    n: not reported in source

    Outcome group
    Acromegaly symptoms · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    A substantial decrease in headache, amount of perspiration, joint pain, and finger circumference occurred in two thirds of the patients.
    3 context sentences
    Summary · context
    One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.
    Summary · context
    Subcutaneous octreotide, 100 micrograms, or placebo every 8 hours for 4 weeks.
    Summary · context
    Four weeks after the end of treatment, patients were randomized to receive 100 or 250 micrograms octreotide subcutaneously every 8 hours for 6 months.
  13. 13HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, pituitary size decreased in 19% receiving low-dose octreotide for 6 months (CI, 5% to 33%).

    In plain wordsIn acromegaly patients, pituitary size decreased in 19% receiving low-dose octreotide for 6 months.

    Peptide
    Octreotide
    Outcome
    Not applicablePituitary shrinkage, low dose
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Endocrine and hormones
    Studied dose
    300 micrograms daily · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Patients with reduced pituitary size
    19%
    low-dose octreotide, 6 months
    CI for proportion
    5 to 33%
    low-dose octreotide, 6 months

    Source sentences

    Summary
    The pituitary size was reduced in 19% (CI, 5% to 33%) and 37% (CI, 22% to 52%) of patients receiving 6 months of low- and high-dose octreotide, respectively.
    3 context sentences
    Summary · context
    One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.
    Summary · context
    Subcutaneous octreotide, 100 micrograms, or placebo every 8 hours for 4 weeks.
    Summary · context
    Four weeks after the end of treatment, patients were randomized to receive 100 or 250 micrograms octreotide subcutaneously every 8 hours for 6 months.
  14. 14HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, pituitary size decreased in 37% receiving high-dose octreotide for 6 months (CI, 22% to 52%).

    In plain wordsIn acromegaly patients, pituitary size decreased in 37% receiving high-dose octreotide for 6 months.

    Peptide
    Octreotide
    Outcome
    Not applicablePituitary shrinkage, high dose
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Endocrine and hormones
    Studied dose
    750 micrograms daily · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Patients with reduced pituitary size
    37%
    high-dose octreotide, 6 months
    CI for proportion
    22 to 52%
    high-dose octreotide, 6 months

    Source sentences

    Summary
    The pituitary size was reduced in 19% (CI, 5% to 33%) and 37% (CI, 22% to 52%) of patients receiving 6 months of low- and high-dose octreotide, respectively.
    3 context sentences
    Summary · context
    One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.
    Summary · context
    Subcutaneous octreotide, 100 micrograms, or placebo every 8 hours for 4 weeks.
    Summary · context
    Four weeks after the end of treatment, patients were randomized to receive 100 or 250 micrograms octreotide subcutaneously every 8 hours for 6 months.
  15. 15HumanNon-randomized trialSafety outcome

    In acromegaly patients, 10% receiving low-dose octreotide developed transient diarrhea.

    In plain wordsIn acromegaly patients, 10% receiving low-dose octreotide developed temporary diarrhea.

    Peptide
    Octreotide
    Outcome
    Not applicableTransient diarrhea, low dose
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    300 micrograms daily · subcutaneousAs given in this study (human).

    Measurements

    Patients with transient diarrhea
    10%
    low-dose octreotide

    Source sentences

    Summary
    Ten percent and 13% of patients in each treatment group developed transient diarrhea; 10% and 14%, biliary sludge; and 6% and 18%, cholelithiasis, respectively.
    3 context sentences
    Summary · context
    One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.
    Summary · context
    Subcutaneous octreotide, 100 micrograms, or placebo every 8 hours for 4 weeks.
    Summary · context
    Four weeks after the end of treatment, patients were randomized to receive 100 or 250 micrograms octreotide subcutaneously every 8 hours for 6 months.
  16. 16HumanNon-randomized trialSafety outcome

    In acromegaly patients, 13% receiving high-dose octreotide developed transient diarrhea.

    In plain wordsIn acromegaly patients, 13% receiving high-dose octreotide developed temporary diarrhea.

    Peptide
    Octreotide
    Outcome
    Not applicableTransient diarrhea, high dose
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    750 micrograms daily · subcutaneousAs given in this study (human).

    Measurements

    Patients with transient diarrhea
    13%
    high-dose octreotide

    Source sentences

    Summary
    Ten percent and 13% of patients in each treatment group developed transient diarrhea; 10% and 14%, biliary sludge; and 6% and 18%, cholelithiasis, respectively.
    3 context sentences
    Summary · context
    One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.
    Summary · context
    Subcutaneous octreotide, 100 micrograms, or placebo every 8 hours for 4 weeks.
    Summary · context
    Four weeks after the end of treatment, patients were randomized to receive 100 or 250 micrograms octreotide subcutaneously every 8 hours for 6 months.
  17. 17HumanNon-randomized trialSafety outcome

    In acromegaly patients, 10% receiving low-dose octreotide developed biliary sludge.

    In plain wordsIn acromegaly patients, 10% receiving low-dose octreotide developed biliary sludge.

    Peptide
    Octreotide
    Outcome
    Not applicableBiliary sludge, low dose
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    300 micrograms daily · subcutaneousAs given in this study (human).

    Measurements

    Patients with biliary sludge
    10%
    low-dose octreotide

    Source sentences

    Summary
    Ten percent and 13% of patients in each treatment group developed transient diarrhea; 10% and 14%, biliary sludge; and 6% and 18%, cholelithiasis, respectively.
    3 context sentences
    Summary · context
    One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.
    Summary · context
    Subcutaneous octreotide, 100 micrograms, or placebo every 8 hours for 4 weeks.
    Summary · context
    Four weeks after the end of treatment, patients were randomized to receive 100 or 250 micrograms octreotide subcutaneously every 8 hours for 6 months.
  18. 18HumanNon-randomized trialSafety outcome

    In acromegaly patients, 14% receiving high-dose octreotide developed biliary sludge.

    In plain wordsIn acromegaly patients, 14% receiving high-dose octreotide developed biliary sludge.

    Peptide
    Octreotide
    Outcome
    Not applicableBiliary sludge, high dose
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    750 micrograms daily · subcutaneousAs given in this study (human).

    Measurements

    Patients with biliary sludge
    14%
    high-dose octreotide

    Source sentences

    Summary
    Ten percent and 13% of patients in each treatment group developed transient diarrhea; 10% and 14%, biliary sludge; and 6% and 18%, cholelithiasis, respectively.
    3 context sentences
    Summary · context
    One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.
    Summary · context
    Subcutaneous octreotide, 100 micrograms, or placebo every 8 hours for 4 weeks.
    Summary · context
    Four weeks after the end of treatment, patients were randomized to receive 100 or 250 micrograms octreotide subcutaneously every 8 hours for 6 months.
  19. 19HumanNon-randomized trialSafety outcome

    In acromegaly patients, 6% receiving low-dose octreotide developed cholelithiasis.

    In plain wordsIn acromegaly patients, 6% receiving low-dose octreotide developed gallstones.

    Peptide
    Octreotide
    Outcome
    Not applicableCholelithiasis, low dose
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    300 micrograms daily · subcutaneousAs given in this study (human).

    Measurements

    Patients with cholelithiasis
    6%
    low-dose octreotide

    Source sentences

    Summary
    Ten percent and 13% of patients in each treatment group developed transient diarrhea; 10% and 14%, biliary sludge; and 6% and 18%, cholelithiasis, respectively.
    3 context sentences
    Summary · context
    One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.
    Summary · context
    Subcutaneous octreotide, 100 micrograms, or placebo every 8 hours for 4 weeks.
    Summary · context
    Four weeks after the end of treatment, patients were randomized to receive 100 or 250 micrograms octreotide subcutaneously every 8 hours for 6 months.
  20. 20HumanNon-randomized trialSafety outcome

    In acromegaly patients, 18% receiving high-dose octreotide developed cholelithiasis.

    In plain wordsIn acromegaly patients, 18% receiving high-dose octreotide developed gallstones.

    Peptide
    Octreotide
    Outcome
    Not applicableCholelithiasis, high dose
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    750 micrograms daily · subcutaneousAs given in this study (human).

    Measurements

    Patients with cholelithiasis
    18%
    high-dose octreotide

    Source sentences

    Summary
    Ten percent and 13% of patients in each treatment group developed transient diarrhea; 10% and 14%, biliary sludge; and 6% and 18%, cholelithiasis, respectively.
    3 context sentences
    Summary · context
    One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.
    Summary · context
    Subcutaneous octreotide, 100 micrograms, or placebo every 8 hours for 4 weeks.
    Summary · context
    Four weeks after the end of treatment, patients were randomized to receive 100 or 250 micrograms octreotide subcutaneously every 8 hours for 6 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.